𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I–II trial of mitoxantrone in acute leukemia: an interim report

✍ Scribed by Zalmen A. Arlin; Gary Dukart; Ingrid Schoch; Arnold Reisman; Joseph Moore; Richard A. Silver; Peter Cassileth; Joseph Bertino; Richard Gams

Publisher
Springer US
Year
1985
Tongue
English
Weight
302 KB
Volume
3
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of mitoxantrone in acut
A phase II study of mitoxantrone in acute leukemia
✍ Tohru Masaoka; Hirotoshi Shibata; Shigeru Oguma; Kiyoyasu Nagai; Teruo Kitani; A 📂 Article 📅 1985 🏛 Springer US 🌐 English ⚖ 297 KB

A phase 1I study of mitoxantrone (Novantrone| dihydroxyanthracenedione) was conducted in 3.5 patients (22 male: 13 female) with acute leukemia. There were 35 cvaluable cases with a mean age of 34 (range 8-61). Twenty-eight patients had acute non-lymphocytic leukemia (ANLL) and seven had acute lympho

Phase I–II trial of VP-16 in the treatme
Phase I–II trial of VP-16 in the treatment of acute nonlymphocytic leukemia and blast crisis of chronic granulocytic leukemia
✍ Mailliard, James A. ;Letendre, Louis ;Dalton, Robert J. ;Levitt, Ralph ;Gerstner 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 442 KB

VP-16 was used to treat newly diagnosed elderly ( 2 6 5 yr) patients with acute nonlymphocytic leukemia (ANLL) and patients with blast crisis of chronic granulocytic leukemia (BI-CGL). Our pilot study indicated that VP-I6 160 mg/m2 intravenously daily for 5 days was well tolerated and suggested a di

A Phase I–II trial of escalating doses o
A Phase I–II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia
✍ Charles A. Koller; Hagop M. Kantarjian; Eric J. Feldman; Susan O'Brien; Mary Bet 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

## BACKGROUND. Cytarabine is an essential drug for inducing remission of acute myelogenous leukemia, and it is also one the most effective drugs used as salvage therapy for patients with all types of relapsed acute leukemia. Nevertheless, there is considerable room for improvement in the treatment